tetano
Editor, Senior Moderator
Cell Rep
. 2021 Jul 20;109479.
doi: 10.1016/j.celrep.2021.109479. Online ahead of print.
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication
Caroline G Williams[SUP] 1 [/SUP], Alexander S Jureka[SUP] 1 [/SUP], Jesus A Silvas[SUP] 1 [/SUP], Anthony M Nicolini[SUP] 2 [/SUP], Stacie A Chvatal[SUP] 2 [/SUP], Jared Carlson-Stevermer[SUP] 3 [/SUP], Jennifer Oki[SUP] 3 [/SUP], Kevin Holden[SUP] 3 [/SUP], Christopher F Basler[SUP] 4 [/SUP]
Affiliations
Abstract
Coronaviruses rely on host membranes for entry, establishment of replication centers, and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we test small molecule inhibitors that target the PI3 kinase VPS34 or fatty acid metabolism for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity. Our studies determine that compounds targeting VPS34 are potent SARS-CoV-2 inhibitors. Mechanistic studies with compounds targeting multiple steps up- and downstream of fatty acid synthase (FASN) identify the importance of triacylglycerol production and protein palmitoylation as requirements for efficient viral RNA synthesis and infectious virus production. Further, FASN knockout results in significantly impaired SARS-CoV-2 replication that can be rescued with fatty acid supplementation. Together, these studies clarify roles for VPS34 and fatty acid metabolism in SARS-CoV-2 replication and identify promising avenues for the development of countermeasures against SARS-CoV-2.
Keywords: COVID-19; SARS coronavirus 2; antiviral; autophagy; coronavirus; fatty acid; membranes; phosphoinositol 3 kinase.
. 2021 Jul 20;109479.
doi: 10.1016/j.celrep.2021.109479. Online ahead of print.
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication
Caroline G Williams[SUP] 1 [/SUP], Alexander S Jureka[SUP] 1 [/SUP], Jesus A Silvas[SUP] 1 [/SUP], Anthony M Nicolini[SUP] 2 [/SUP], Stacie A Chvatal[SUP] 2 [/SUP], Jared Carlson-Stevermer[SUP] 3 [/SUP], Jennifer Oki[SUP] 3 [/SUP], Kevin Holden[SUP] 3 [/SUP], Christopher F Basler[SUP] 4 [/SUP]
Affiliations
- PMID: 34320401
- DOI: 10.1016/j.celrep.2021.109479
Abstract
Coronaviruses rely on host membranes for entry, establishment of replication centers, and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we test small molecule inhibitors that target the PI3 kinase VPS34 or fatty acid metabolism for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity. Our studies determine that compounds targeting VPS34 are potent SARS-CoV-2 inhibitors. Mechanistic studies with compounds targeting multiple steps up- and downstream of fatty acid synthase (FASN) identify the importance of triacylglycerol production and protein palmitoylation as requirements for efficient viral RNA synthesis and infectious virus production. Further, FASN knockout results in significantly impaired SARS-CoV-2 replication that can be rescued with fatty acid supplementation. Together, these studies clarify roles for VPS34 and fatty acid metabolism in SARS-CoV-2 replication and identify promising avenues for the development of countermeasures against SARS-CoV-2.
Keywords: COVID-19; SARS coronavirus 2; antiviral; autophagy; coronavirus; fatty acid; membranes; phosphoinositol 3 kinase.